CytomX Therapeutics (NASDAQ: CTMX) Surges 5.13% on Strategic Developments and Key Updates

On January 15, 2026, CytomX Therapeutics (NASDAQ: CTMX) surged 5.1345% in pre-market trading, signaling renewed investor confidence ahead of key updates and strategic developments.

Recent developments include the appointment of Rachael Lester as Chief Business Officer in October 2025, leveraging her expertise in partnerships and capital formation to advance the company’s pipeline, including lead candidates CX-2051 for colorectal cancer and CX-801 for melanoma. This leadership change underscores CytomX’s focus on expanding its PROBODY® platform and strategic collaborations.

Positive interim data from the Phase 1 study of CX-2051, an EpCAM-targeting antibody-drug conjugate, showed a 28% confirmed response rate in advanced colorectal cancer patients, with a favorable safety profile. The trial, now enrolling 73 patients across three dose cohorts, remains on track for a Q1 2026 data update despite a single Grade 5 adverse event reported in July 2025.

Financially, CytomX raised $100 million through a stock offering in May 2025, extending its cash runway to Q2 2027. The company also reported Q2 2025 results, highlighting reduced operating expenses and a $5 million milestone payment from Astellas. These factors, combined with a planned Phase 2 trial for CX-2051 in 2026, position CytomX to advance its clinical programs while maintaining financial stability.